Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:27:30 EST Tue 13 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:EXEL - EXELIXIS INC - https://www.exelixis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EXEL - Q0.827.24·44.600.144.06+0.020.04,143.0180,07431,32442.59  45.06  42.0549.40  31.90Jan 12Jan 1115 min RT 2¢

Recent Trades - Last 10 of 31324
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-11 16:00U:EXELNews ReleaseExelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
2026-01-07 08:00U:EXELNews ReleaseExelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
2026-01-06 16:05U:EXELNews ReleaseExelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
2025-12-12 10:31U:EXELNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-12-03 16:05U:EXELNews ReleaseExelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
2025-11-06 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
2025-11-04 16:05U:EXELNews ReleaseExelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-21 16:05U:EXELNews ReleaseExelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
2025-10-21 07:00U:EXELNews ReleaseSynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
2025-10-20 02:30U:EXELNews ReleaseExelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
2025-10-18 03:00U:EXELNews ReleaseExelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX(TM) (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
2025-08-29 17:47U:EXELNews ReleaseExelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
2025-08-27 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
2025-07-28 16:05U:EXELNews ReleaseExelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
2025-07-24 17:04U:EXELNews ReleaseExelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX(TM) (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
2025-07-14 16:05U:EXELNews ReleaseExelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
2025-06-22 17:00U:EXELNews ReleaseExelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
2025-06-20 06:54U:EXELNews ReleaseExelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX(TM) (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
2025-05-22 17:17U:EXELNews ReleaseExelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
2025-05-22 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June